Biocon also said it has secured a global settlement and licence agreement with Genentech, allowing Pebrilzo’s earliest licensed US launch in 2028.
The post Biocon secures USFDA approval for Pebrilzo, its fifth cancer biosimilar appeared first on Home Page.
